Inventiva S.A. (NASDAQ:IVA) 2022 Full Year Results Earnings Conference Call March 30, 2023 8:00 AM ET

Company Participants

Frédéric Cren – Chief Executive Officer

Jean Volatier – Chief Financial Officer

Michael Cooreman – Chief Medical Officer

Conference Call Participants

Seamus Fernandez – Guggenheim Securities

Annabel Samimy – Stifel

Ed Arce – H.C. Wainwright

Frédéric Gomez – Pharmium Securities

Operator

Good day and thank you for standing by. Welcome to the Inventiva 2022 Full Year Results Call and Webcast. At this time, all participants are in listen-only mode. After the speakers' presentation, there will be a question-and-answer session. [Operator Instructions] Please note that today's conference is being recorded.

I would now like to hand over to your speaker, Mr. Frédéric Cren. Please go ahead, sir.

Frédéric Cren

Thank you, operator, and welcome to everybody to this full year 2022 financial results. As usual, I will be making with my colleagues forward-looking statements. So please have a look at the regulatory documentation that is available on our website. In terms of speakers today, I'm very happy as usual to have Pierre with us our CSO and Co-Founder; Michael, our CMO, will go through an update of our three important clinical trials with lanifibranor, of course, the Phase III, but also two Phase II that are ongoing. And then Jean will conclude the presentation with an update on the financials. Of course, at the end of the session, we will have a Q&A session.

So let me give you, first of all, some highlights for the full year. So let's start with our lead program, lani in NASH, and start with NATiV3, where we've been, I would say, very happy to work and extend, develop the Phase III in 23 countries. And now we have more than 350 clinical sites that are active and more than 300 that have screened at least a patient. We have throughout the year, and we continue to do so, implemented a series of measure to boost enrollment and I would say that this continues throughout 2023.

We have done many things and we're very proud of those and grateful to our team. We have reviewed and implemented a new process to speed up our biopsy are analyzed. We have trained sites. We have put in place incentives. We have included site networks, which are specialized. We have a strong NASH expertise. And we are – also have closed sites that were not performing to our expectations. We have developed patient material including opening recently the patient website. We have provided support to pre-screening activities to sites, including providing a screening algorithm to better identify the patients.